Vivani Medical, Inc. · NASDAQ:VANI
Vivani Medical — Second Sight Medical Products — IPO Roadshow (April 2020)
14 slides from Vivani Medical's IPO roadshow presentation, Apr 29, 2020
Slide 1: Second Sight Medical Products Investor Presentation
Second Sight Medical Products, Inc. (NASDAQ: EYES) Discover Life in a New Light® Investor Presentation Filed pursuant to Rule 433 Dated April 29 , 2020 Issuer Free Writing Prospectus supplementing the Preliminary Prospectus Supplement dated April 29 , 2020 and the Prospectus dated November 9, 2017 R
Slide 2: Forward-looking statements and offering legend
• The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the "safe harbor" crea
Slide 3: Highlights
Highlights 3 Established technology with 10+ years proven implant durability Proprietary algorithms for artificial vision Over 85 issued U.S. patents for Orion, over 300 patents in total with 40 pending applications Orion leverages Argus II technology platform Argus II is an established therapy in o
Slide 4: What is Orion? How Orion Technology Works?
What is Orion? 4 How Orion Technology Works? https://youtu.be/bLy9owi6s9c
Slide 5: Orion Patient Stories
Orion Patient Stories 5 ABC 6 Philadelphia https://6abc.com/health/brain-implant-gives-blind-new-way-to-see-worldaround- them/5553255/ The Story of Medtech https://thestoryofmedtech.org/story/seeinganew- artificial-vision-richards-story CNET What the Future: Artificial Vision for the Blind https://w
Slide 6: Orion Has the Potential to Treat Virtually All Forms of Blindness
Estimated individuals in our initial addressable market in the U.S. Orion ® Has the Potential to Treat Virtually All Forms of Blindness 6 U.S. Market 50,000- 100,000 with Light Perception or worse 500,000+ Legally Blind Initial addressable market Legally blind due to retinitis pigmentosa, glaucoma,
Slide 7: Orion Market Potential Grows Significantly In Future Years
Orion ® Market Potential Grows Significantly In Future Years 7 individuals in our initial addressable market in the U.S.1 50k-100k individuals in our future addressable market worldwide2 150k-300k individuals in our addressable market worldwide with label expansion into better vision3 600k-1.2M 1 -
Slide 8: Orion Interim Study Results Support Advancement to Pivotal
Orion® Interim Study Results Support Advancement to Pivotal 8 Ongoing six subject Early Feasibility Study at UCLA Medical Center and Baylor Initial results from first six subjects at 12 months Safety Square Localization (SL) Direction of Motion (DOM) FLORA 1 SAE (seizure) 6 AEs (2 subjects, 4* subje
Slide 9: Orion US Reimbursement Strategy
Orion US Reimbursement Strategy 9 While Medicare is the largest & most critical payer for Orion, commercial and VA will play an important role too, given a relatively younger population With FDA Breakthrough Device Designation for Orion and strong CMS Argus history, Second Sight is proactively engag
Slide 10: Key Milestones to Commercialization
KEY MILESTONES TO COMMERCIALIZATION • FLORA‐20 validation • FDA agreement on pivotal trial design • Submit IDE for Orion II • IDE approval • 1st Orion II implant in pivotal trial • Last Orion II implant in pivotal trial • Study follow‐up period (12 months postimplant) • Interim study results availab
Slide 11: Partnering with Other Firms to Develop and Integrate Assistive Technologies with Orion
Partnering with Other Firms to Develop and Integrate Assistive Technologies with Orion Eye Tracking Move the implant field of view in conjunction with the movement of the user’s eyes Thermal Imaging Infrared imaging would allow users to visualize warm objects such as people in a room Depth-Based Dec
Slide 12: Capitalization Table
Capitalization Table Pre-Offering 12 Common Shares Outstanding 15,657,700 Warrants (WAEP1 $11.76) 7,682,244 Options (WAEP $18.82) 566,079 1 One class of warrants outstanding at exercise price of $11.76. Listed as EYESW
Slide 13: Second Sight Investment Highlights
Second Sight Investment Highlights Orion represents a multi-billion dollar opportunity Potential to treat nearly all forms of blindness including retinitis pigmentosa, diabetic retinopathy, glaucoma, optic nerve disease and eye injury Six subject feasibility study at UCLA and Baylor has positive res
Slide 14: Contacts
Contacts Second Sight Medical Products, Inc. 12744 San Fernando Road Suite 400 Sylmar, CA 91342 Main: 818-833-5000 www.secondsight.com John Blake CFO jblake@secondsight.com Institutional Investor Relations Lisa Wilson President In-Site Communications, Inc. Direct: 212-452-2793 lwilson@insitecony.com
Second Sight Medical Products — IPO Roadshow (April 2020) on 6ix